Our vision is to make DiagMMR the global standard test for Lynch cancer syndrome diagnosis.

DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

DiagMMR Laboratory


DiagMMR innovation has several benefits compared to the current diagnostic tools:

Validation Study

Our research team published a peer-reviewed article in Cancer Research Communications in March 2023, showing the results of the clinical validation of the DiagMMR test. It confirms the high accuracy of the functional DiagMMR test in identifying individuals with inherited deficiency of the mismatch repair function.

The function plays a vital role in cancer development. Furthermore, the test was shown to have an exceptional specificity (100%) and high sensitivity and accuracy, overcoming the complexity of other existing testing methods, and improving the ability to recognize individuals with Lynch syndrome.

Learn more about this important piece of work in our dedicated article.

DiagMMR Validation
Click the image to access the full article

Invest today!

LS CancerDiag has launched a funding round in collaboration with Springvest

The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.